AKonnects with Dr. Aman Kapoor: Your Professional Connect with Health Updates

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, like dapagliflozin and empagliflozin, have brought a paradigm shift in the management of heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes. These drugs have been celebrated for reducing mortality, hospitalizations, and improving overall patient outcomes. However, no solution is without questions. With heart failure and diabetes posing dual challenges in India, where do SGLT-2 inhibitors truly stand? Are they a long-term game-changer or just one step in a larger journey? The India Perspective The Reality of Disease Burden India faces over 10 million heart failure cases and ranks among the highest globally with 77 million diabetic patients . With diabetes and cardiovascular disease so deeply intertwined, therapies like SGLT-2 inhibitors promise much-needed relief. The Challenges Adoption : While global guidelines highlight their efficacy, Indian practitioners are still exploring how these drugs fare in real-world...